ULTI_1170x120_2-25-20

U.S. Drug Enforcement Administration (DEA)

CURE Pharmaceutical to manufacture pharmaceuticals using whole cannabis plant

CURE Pharmaceutical to manufacture pharmaceuticals using whole cannabis plant

OXNARD, Calif. – CURE Pharmaceutical Tuesday announced it has broadened its U.S. Drug Enforcement Administration (DEA) license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD). This license allows CURE to take advantage of its latest U.S. Patent No. 10,238,705 issuing this month for the extraction and purification of